{"altmetric_id":21689706,"counts":{"readers":{"mendeley":2,"citeulike":0,"connotea":0},"total":{"posts_count":1},"policy":{"unique_users_count":1,"unique_users":["nice"],"posts_count":1}},"citation":{"altmetric_jid":"4f6fa5153cf058f6100036ec","authors":["K Tolley","C Goad","Y Yi","PA Maroudas","G Thompson"],"doi":"10.1016\/s1098-3015(11)72012-5","first_seen_on":"2017-07-09T19:05:58+00:00","issns":["10983015"],"journal":"Value in Health (Elsevier Science)","last_mentioned_on":1371772800,"links":["http:\/\/dx.doi.org\/10.1016\/S1098-3015(11)72012-5"],"pubdate":"2010-11-01T00:00:00+00:00","publisher_subjects":[{"name":"Public Health And Health Services","scheme":"era"},{"name":"Applied Economics","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"title":"PCN117 UTILITY ELICITATION STUDY IN THE UK GENERAL PUBLIC FOR LATE STAGE CHRONIC LYMPHOCYTIC LEUKEMIA","type":"article","mendeley_url":"http:\/\/www.mendeley.com\/research\/pcn117-utility-elicitation-study-uk-general-public-late-stage-chronic-lymphocytic-leukemia-1"},"altmetric_score":{"score":3,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":3},"context_for_score":{"all":{"total_number_of_other_articles":8036413,"mean":6.8198925358698,"rank":2011910,"this_scored_higher_than_pct":61,"this_scored_higher_than":4923028,"rank_type":"exact","sample_size":8036413,"percentile":61},"similar_age_3m":{"total_number_of_other_articles":104642,"mean":10.730783306735,"rank":32012,"this_scored_higher_than_pct":68,"this_scored_higher_than":71500,"rank_type":"exact","sample_size":104642,"percentile":68},"this_journal":{"total_number_of_other_articles":1551,"mean":3.8609793548387,"rank":314,"this_scored_higher_than_pct":66,"this_scored_higher_than":1034,"rank_type":"exact","sample_size":1551,"percentile":66},"similar_age_this_journal_3m":{"total_number_of_other_articles":10,"mean":1.1666666666667,"rank":2,"this_scored_higher_than_pct":80,"this_scored_higher_than":8,"rank_type":"exact","sample_size":10,"percentile":80}}},"demographics":{"users":{"mendeley":{"by_status":{"Student  > Ph. D. Student":1,"Student  > Master":1},"by_discipline":{"Medicine and Dentistry":1,"Social Sciences":1}}}},"posts":{"policy":[{"title":"Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy: Colorectal cancer (metastatic) - aflibercept: evaluation report","url":"https:\/\/www.nice.org.uk\/guidance\/TA307\/documents\/colorectal-cancer-metastatic-aflibercept-evaluation-report2","license":"public","citation_ids":[1176911,2414820,5898084,2414824,7406858,15777348,931179,464330,2784654,21689706,15777350,945708,15777353,14491278,1983833,1429744,15777359,15777363,15777366,235707,589600,21689709,15777372,15777374,21689711,15777379,15777381,3219486,15777390,15777395,5586465,1903846,15750507,6073229,12918022,210531,3174285,380641,3368425,15777412,21689713,15777421,6077045,210494,2407679,15777441,15777444,8078462,850081,1752525,15777464,1223045,15777470,809217,2416454,210390,15660205,15777483,2480220,381688,1834844,5613031,15777502,15777511,15777516,21689717,21689718,8154575,15777523,1145378,15777353],"posted_on":"2013-06-21T00:00:00+00:00","source":{"name":"National Institute for Health and Care Excellence","description":"The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.","geo":{"country":"GB"}},"page_url":"https:\/\/www.nice.org.uk\/guidance\/ta307\/evidence","collections":[],"author":{"image":"https:\/\/s3.amazonaws.com\/cache.altmetric.com\/policy\/thumbnails\/thumbnail-3912e06cb81343df2459903b2a5cfc2d0c39c03fcd51530889b3f7c36cac6ee7.jpg"}}]}}